莲必治注射液联合头孢曲松钠他唑巴坦钠治疗老年肺炎的临床效果

Abstract
Figure/Table
References (15)
Related Citation (15)

Download: PDF (0 KB) HTML (33 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the clinica effect of Lianbizhi Injection combined with Ceftriaxone Sodium and Tazobactam Sodium in the treatment of senile pneumonia. Methods A total of 90 elderly patients with pneumonia admitted to our hospital from June 2017 to June 2018 were selected as the study subjects. According to the random number table method, they were divided into the control group (45 cases) and the combined group (45 cases). The control group was treated with Ceftriaxone Sodium and Tazobactam Sodium, the combined group was treated with Lianbizhi Injection and Ceftriaxone Sodium and Tazobactam Sodium. After 2 weeks of treatment, the improvement of symptoms,medication effect and inflammation indicators before and after treatment were compared between the two groups. Results The antipyretic time, cough disappearance time and wheezing time in the combined group were shorter than those in the control group, and the differences were statistically significant (P＜0.05). The total effective rate of the combined group was higher than that of the control group , and the difference was statistically significant (P＜0.05). After treatment, the levels of C-reactive protein (CRP), tumor necrosis factor-α (TNF-α) and interleukin-6 (IL-6) in the two groups were lower than those before treatment, and the levels of CRP, TNF-α and IL-6 in the combined group were lower than those in the control group, and the differences were statistically significant (P＜0.05). Conclusion On the basis of Ceftriaxone Sodium and Tazobactam Sodium combined with Lianbizhi Injection can significantly improve the clinical symptoms and inflammatory indicators of senile pneumonia patients, with good application effect.

Key words： Elderly； Pneumonia； Lianbizhi Injection； Ceftriaxone Sodium and Tazobactam Sodium； Inflammatory indicators

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GUO Yu-mei
	GENG Li-li
	SHU Jiao-jie
	ZHANG Yun
	XU Xian-nan
	ZANG Shi-guo
	LIU Hao

Cite this article:

GUO Yu-mei,GENG Li-li,SHU Jiao-jie, et al. Clinical effect of Lianbizhi Injection combined with Ceftriaxone Sodium and Tazobactam Sodium in the treatment of senile pneumonia[J]. 中国当代医药, 2019, 26(9): 41-43.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2019/V26/I9/41

[2]	孙高中，钱先中，曹畅.注射用头孢曲松钠他唑巴坦钠致药物性皮疹1 例[J].中国药业，2018，27（3）：96.
[3]	中华医学会呼吸病学分会.社区获得性肺炎诊断和治疗指南[J].中国实用乡村医生杂志，2013，29（2）：158-160.
[1]	Park HJ，Lee SM，Choe J，et al.Prediction of treatment response in patients with chronic obstructive pulmonary disease by determination of airway dimensions with baseline computed tomography[J].Korean J Radiol，2019，20（2）：304-312.
[4]	郑筱萸.中药新药临床研究指导原则（试行）[M].北京：中国医药科技出版社，2002.
[5]	汤克松.痰热清联合头孢曲松钠治疗急性肺炎的临床有效性[J].生物技术世界，2016，8（4）：192.
[6]	王朋.分析痰热清联合头孢曲松钠治疗急性肺炎的临床疗效[J].世界最新医学信息文摘，2018，18（36）：159.
[7]	段纪芳.老年人社区获得性肺炎危险因素临床分析[J].临床合理用药杂志，2016，9（18）：35-36.
[8]	杨永亮.左氧氟沙星联合头孢曲松钠治疗社区获得性肺炎疗效分析[J].内蒙古医学杂志，2016，48（6）：721-723.
[9]	谭化，张秀敬，李娜.莲必治注射液联合头孢曲松钠他唑巴坦钠治疗老年肺炎的临床研究[J].现代药物与临床，2018，33（11）：2872-2875.
[10]	杜家杰.十味龙胆花颗粒联合头孢曲松钠治疗老年社区获得性肺炎的临床研究[J].现代药物与临床，2018，33（4）：813-816.
[11]	杨丽，蒋玉华，张雪，等.老年患者吸入性肺炎相关因素分析与预防研究[J].中华医院感染学杂志，2016，26（13）：2948-2950.
[12]	吴振起，王贵帮，严峰，等.清燥救肺汤及其分解剂对肺炎支原体感染模型小鼠免疫炎症的影响[J].国际中医中药杂志，2018，40（5）：442.
[13]	郑宏宇.急性肺炎患者应用痰热清联合头孢曲松钠治疗的效果研究[J].临床医药文献电子杂志，2017，4（13）：189.
[14]	Bellou V，Belbasis L，Konstantinidis AK，et al.Elucidating the risk factors for chronic obstructive pulmonary disease：an umbrella review of meta-analyses[J].Int J Tuberc Lung Dis，2019，23（1）：58-66.
[15]	孙羽.清开灵注射液联合头孢曲松钠治疗小儿肺炎的临床观察[J].中国实用医药，2017，12（30）：141-142.